Business
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General
About this update from Proqr Therapeutics N.v.
[{"type":"text","content":"Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with leadership oversight of Axiomer® RNA-editing platform technologyJohn Maraganore, PhD, former Founding CEO of Alnylam Pharmaceuticals, extends commitment as a strategic advisor to the Supervisory BoardSmital Shah, Chief Business and Financial Officer, to leave the Company as part of planned transition at the end of 2022; search has been initiated for a new Chief Financial Officer LEIDEN, Netherlands & CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that its 2022 Annual General Meeting of Shareholders will take place on Thursday, June 30, 2022 at 14:00 CET (08:00 EDT) via videoconference (the “AGM”). The Company also announced the following updates to its leadership. ProQR has appointed René Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel. Mr. Beukema is also nominated to join the Management Board, subject to approval by shareholders at the AGM. Mr. Beukema is a seasoned M&A and equity capital markets executive and an experienced corporate lawyer who previously served as the Company's Chief Corporate Development Officer and General Counsel from September 2013 to December 2018. Most recently, he has been General Counsel & Chief Corporate Development at Frame Cancer Therapeutics. Prior to his initial tenure at the Company, Mr. Beukema served as General Counsel and Corporate Secretary of Crucell N.V. for twelve years, following his positions as Senior Legal Counsel at GE Capital / TIP Europe and Legal Counsel at TNT Express Worldwide. Mr. Beukema was also a venture partner of Aescap Venture, a life sciences venture capital firm from 2011 to 2012 and is co-founder and advisor of Mytomorrows N.V., a Dutch life sciences company. He holds a post-doctoral degree in corporate law from the University of Nijmegen in co-operation with the Dutch Association of In-house Counsel (Nederlands Genootschap van Bedrijfsjuristen) and a master's degree in Dutch law fr...